I think the rules vary tremendously by country, and the rules are different in different aspects.
For example, the United States is typically seen as the aggressor on intellectual property, if you will, and as the country that's trying to promote higher levels of protection. If we compare, in the pharmaceutical space, the United States and Canada, Canada has now, or will have after CETA, patent term extensions. The U.S. has patent term extensions. Canada has a very restrictive patent linkage system that is very costly and that we're hoping to improve.
My point is that the U.S. is the aggressor that had been seen to be promoting strong IP, but in terms of Canada I think we already have strong IP, so we're not as targeted as some countries.